title: Comparison of PET imaging with 64Cu-liposomes and 18F-FDG in the 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster buccal pouch model of oral dysplasia and squamous cell carcinoma.
abstract: OBJECTIVE
  Currently, 2-deoxy-2-[(18)F]fluoro-D-glucose ((18)F-FDG) is the gold standard radiotracer for staging of head and neck cancer; however, the low sensitivity of this tracer can impede detection of early lesions. (64)Cu-liposomes accumulate in various cancers and provide both a sensitive tracer and an indication of the biodistribution of nanotherapeutics. Here, the accumulation of (64)Cu-liposomes in early and established cancers is assessed and compared with (18)F-FDG in a head and neck cancer model.
  
  
  METHODS
  Lesions ranging from mild dysplasia to squamous cell carcinoma were induced in a hamster model of head and neck cancer by topical application of 7,12-dimethylbenz[a]anthracene to the buccal pouch. The hamsters were imaged with micro-positron emission tomography using (18)F-FDG and (64)Cu-liposomes.
  
  
  RESULTS
  At 24 h postinjection, (64)Cu-liposome accumulation exceeded the accumulation of (18)F-FDG in every pathologic grade. The lesion-to-cheek pouch (background) ratio and lesion-to-brain ratio were also higher for (64)Cu-liposomes than for (18)F-FDG.
  
  
  CONCLUSIONS
  Imaging of a nanotracer such as (64)Cu-liposomes can improve the visualization of head and neck tumors. Accumulation of liposomal particles in head and neck tumors over various pathologic grades averaged 3.5%ID/cc demonstrating the potential for liposomal therapy with targeted chemotherapeutic agents.
authors.affiliation: Department of Biomedical Engineering, University of California, Davis, 451 Health Sciences Drive, Davis, CA, 95616, USA.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Mahakian
authors.forename: D Gregory
authors.initials: DG
authors.lastname: Farwell
authors.forename: Hua
authors.initials: H
authors.lastname: Zhang
authors.forename: Jai Woong
authors.initials: JW
authors.lastname: Seo
authors.forename: Brian
authors.initials: B
authors.lastname: Poirier
authors.forename: Steven P
authors.initials: SP
authors.lastname: Tinling
authors.forename: Alaa M
authors.initials: AM
authors.lastname: Afify
authors.forename: Eric M
authors.initials: EM
authors.lastname: Haynam
authors.forename: David
authors.initials: D
authors.lastname: Shaye
authors.forename: Katherine W
authors.initials: KW
authors.lastname: Ferrara
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D001921:Brain / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced / Q000000981:diagnostic imaging* / Q000473:pathology; D003301:Copper Radioisotopes; D006224:Cricetinae; D004195:Disease Models, Animal; D019788:Fluorodeoxyglucose F18; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging; D006321:Heart / Q000000981:diagnostic imaging; D008081:Liposomes; D009062:Mouth Neoplasms / Q000139:chemically induced / Q000000981:diagnostic imaging* / Q000473:pathology; D049268:Positron-Emission Tomography
chemical_list: D003301:Copper Radioisotopes; D008081:Liposomes; D019788:Fluorodeoxyglucose F18; D015127:9,10-Dimethyl-1,2-benzanthracene
references.citation: Singapore Med J. 2009 Feb;50(2):139-46
references.pmid: 19296028
references.citation: Arch Otolaryngol Head Neck Surg. 2010 Feb;136(2):126-33
references.pmid: 20157056
references.citation: Cancer Res. 2012 Mar 15;72(6):1485-93
references.pmid: 22282664
references.citation: J Clin Oncol. 2008 Feb 1;26(4):612-9
references.pmid: 18235120
references.citation: Am J Nucl Med Mol Imaging. 2013;3(1):32-43
references.pmid: 23342299
references.citation: Opt Lett. 2009 Jul 1;34(13):2081-3
references.pmid: 19572006
references.citation: J Oncol. 2009;2009:208725
references.pmid: 19707528
references.citation: Int J Pharm. 2011 Jan 17;403(1-2):170-7
references.pmid: 20934495
references.citation: J Oral Pathol Med. 2009 May;38(5):455-62
references.pmid: 19141066
references.citation: Ann Nucl Med. 2008 Apr;22(3):177-84
references.pmid: 18498032
references.citation: Head Neck Oncol. 2012 Jan 13;4:1
references.pmid: 22244087
references.citation: Clin Cancer Res. 2006 Nov 15;12(22):6716-22
references.pmid: 17121891
references.citation: Ear Nose Throat J. 2006 Feb;85(2):74
references.pmid: 16579185
references.citation: Nat Rev Drug Discov. 2005 Feb;4(2):145-60
references.pmid: 15688077
references.citation: Chem Biol Interact. 2010 Dec 5;188(3):616-22
references.pmid: 20816777
references.citation: J Control Release. 2010 Apr 2;143(1):13-22
references.pmid: 20006659
references.citation: J Oral Maxillofac Surg. 2009 Aug;67(8):1649-55
references.pmid: 19615577
references.citation: Bioconjug Chem. 2008 Dec;19(12):2577-84
references.pmid: 18991368
references.citation: Clin Cancer Res. 2011 Feb 1;17(3):550-9
references.pmid: 21106723
references.citation: J Clin Oncol. 2011 Feb 20;29(6):739-46
references.pmid: 21189382
references.citation: Bioconjug Chem. 2010 Jul 21;21(7):1206-15
references.pmid: 20568726
references.citation: Otolaryngol Head Neck Surg. 2010 Jun;142(6):838-44
references.pmid: 20493355
references.citation: Adv Drug Deliv Rev. 2011 Mar 18;63(3):161-9
references.pmid: 20869415
references.citation: Nat Rev Cancer. 2011 Jan;11(1):9-22
references.pmid: 21160525
references.citation: J Clin Oncol. 2011 Nov 10;29(32):4294-301
references.pmid: 21969503
references.citation: Head Neck Oncol. 2009 Oct 14;1:36
references.pmid: 19828033
references.citation: Adv Drug Deliv Rev. 2004 Apr 29;56(8):1177-92
references.pmid: 15094214
references.citation: Mol Pharm. 2010 Feb 1;7(1):12-21
references.pmid: 19621944
references.citation: Prog Exp Tumor Res. 1972;16:518-38
references.pmid: 4557243
references.citation: Biomaterials. 2008 Apr;29(12):1976-88
references.pmid: 18255141